^
Association details:
| Biomarker: | SLC22A1 480CC + SLC22A1 1222AG + SLCO1B3 334TT + SLCO1B3 334TG |
|---|---|
| Cancer: | Chronic Myeloid Leukemia |
| Drug: | imatinib (YD312) (c-KIT inhibitor, SCF signal transduction pathway inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Association of SLC22A1,SLCO1B3 Drug Transporter Polymorphisms and Smoking with Disease Risk and Cytogenetic Response to Imatinib in Patients with Chronic Myeloid Leukemia
Published date:
06/15/2021
Excerpt:
To determine whether polymorphisms of SLC22A1 and SLCO1B3 genes could predict imatinib (IM) response and chronic myeloid leukemia (CML) risk....The double combinations of SLC22A1c.480CC and c.1222AG polymorphisms with SLCO1B3c.334TT/TG were significantly associated with complete cytogenetic response (CCyR) (P <.05; OR> 7).
DOI:
10.1093/labmed/lmab023
